Darren R. Hodgson

Defining actionable mutations for oncology therapeutic development

Jonathan R. Dry, Zhongwu Lai, J. Carl Barrett, 2016, Nature Reviews Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

B. Gilks, J. Ledermann, A. Gutin, 2018, British Journal of Cancer.

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

James X. Sun, Roman Yelensky, Zhongwu Lai, 2017, Oncotarget.

Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization

E. Kohn, D. Bowtell, A. Oza, 2017, Clinical Cancer Research.